Sodium-dependent Phosphate Transporter NaPi2b As a Potential Predictive Marker for Targeted Therapy of Ovarian Cancer

Overview

Journal Biochem Biophys Rep

Specialty Biochemistry

Date 2021 Sep 10

PMID 34504954

Citations 8

Authors

A K Nurgalieva

V E Popov

V S Skripova

L F Bulatova

D V Savenkova

R A Vlasenkova

S Z Safina

E Zh Shakirova

V V Filonenko

M V Bogdanov

R G Kiyamova

Affiliations

Soon will be listed here.

Abstract

The high mortality rate from ovarian cancer is due to the asymptomatic nature of the course of the disease, which leads to the diagnosis of ovarian cancer in later stages. The sodium-dependent phosphate transporter NaPi2b encoded by gene is expressed in 80-90% of epithelial ovarian cancers and used as a target for therapeutic antibodies XMT-1536, and XMT-1592, which are derived from MX35 antibodies and used in clinical trials for the treatment of ovarian and lung cancers. In this work, we aimed to evaluate NaPi2b as a molecular marker for diagnostics and predicting the course and outcome of ovarian cancer disease. Quantitative analysis of gene expression in ovarian tumor tissue was performed at the level of transcription and translation using real-time PCR, droplet digital PCR and Western blot analysis respectively. Statistical analysis was performed taking into account various clinicopathological characteristics of the ovarian cancer patients, including the stage of the disease, the tumor grade, the applying of neoadjuvant chemotherapy and the presence of ascites. In this work, we demonstrated that the expression of the human NaPi2b (hNaPi2b) transporter is downregulated in the tumors of patients receiving neoadjuvant therapy and during the development of disease. The data suggest that the level of expression of the gene can serve as a potential marker for the monitoring and predicting responses to neoadjuvant and targeted therapy in patients with ovarian cancer.

Citing Articles

Targeted radiopharmaceuticals: an underexplored strategy for ovarian cancer.

Crabbe M, Opsomer T, Vermeulen K, Ooms M, Segers C Theranostics. 2024; 14(16):6281-6300.

PMID: 39431018 PMC: 11488094. DOI: 10.7150/thno.99782.

Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy.

Malik S, Sikander M, Bell N, Zubieta D, Bell M, Yallapu M J Ovarian Res. 2024; 17(1):161.

PMID: 39118097 PMC: 11308542. DOI: 10.1186/s13048-024-01485-2.

Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses.

Malli Cetinbas N, Monnell T, Soomer-James J, Shaw P, Lancaster K, Catcott K Nat Commun. 2024; 15(1):5842.

PMID: 38992037 PMC: 11239908. DOI: 10.1038/s41467-024-49932-4.

Exploring the Potential of Antibody-Drug Conjugates in Targeting Non-small Cell Lung Cancer Biomarkers.

Khadela A, Megha K, Shah V, Soni S, Shah A, Mistry H Clin Med Insights Oncol. 2024; 18:11795549241260534.

PMID: 38911453 PMC: 11193349. DOI: 10.1177/11795549241260534.

Selected markers of ovarian cancer and their relation to targeted therapy (Review).

Markowska A, Kojs Z, Twardawa D, Pietras J, Markowska J Exp Ther Med. 2024; 27(5):236.

PMID: 38628658 PMC: 11019661. DOI: 10.3892/etm.2024.12523.

References

Gryshkova V, Goncharuk I, Gurtovyy V, Khozhayenko Y, Nespryadko S, Vorobjova L . The study of phosphate transporter NAPI2B expression in different histological types of epithelial ovarian cancer. Exp Oncol. 2009; 31(1):37-42. View

Kiyamova R, Gryshkova V, Ovcharenko G, Lituyev D, Malyuchik S, Usenko V . Development of monoclonal antibodies specific for the human sodium-dependent phosphate co-transporter NaPi2b. Hybridoma (Larchmt). 2008; 27(4):277-84. DOI: 10.1089/hyb.2008.0015. View

Bobko A, Eubank T, Driesschaert B, Dhimitruka I, Evans J, Mohammad R . Interstitial Inorganic Phosphate as a Tumor Microenvironment Marker for Tumor Progression. Sci Rep. 2017; 7:41233. PMC: 5259743. DOI: 10.1038/srep41233. View

Bookman M . Can we predict who lives long with ovarian cancer?. Cancer. 2020; 125 Suppl 24:4578-4581. DOI: 10.1002/cncr.32474. View

Bodyak N, Mosher R, Yurkovetskiy A, Yin M, Bu C, Conlon P . The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b. Mol Cancer Ther. 2021; 20(5):896-905. DOI: 10.1158/1535-7163.MCT-20-0183. View

Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani A . Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother. 2004; 58(1):24-38. DOI: 10.1016/j.biopha.2003.11.003. View

Yin B, Kiyamova R, Chua R, Caballero O, Gout I, Gryshkova V . Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. Cancer Immun. 2008; 8:3. PMC: 2935786. View

Huqun , Izumi S, Miyazawa H, Ishii K, Uchiyama B, Ishida T . Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis. Am J Respir Crit Care Med. 2006; 175(3):263-8. DOI: 10.1164/rccm.200609-1274OC. View

Murer H, Forster I, Biber J . The sodium phosphate cotransporter family SLC34. Pflugers Arch. 2003; 447(5):763-7. DOI: 10.1007/s00424-003-1072-5. View

10.

Shyian M, Gryshkova V, Kostianets O, Gorshkov V, Gogolev Y, Goncharuk I . Quantitative analysis of SLC34A2 expression in different types of ovarian tumors. Exp Oncol. 2011; 33(2):94-8. View

11.

Hashimoto M, Wang D, Kamo T, Zhu Y, Tsujiuchi T, Konishi Y . Isolation and localization of type IIb Na/Pi cotransporter in the developing rat lung. Am J Pathol. 2000; 157(1):21-7. PMC: 1850224. DOI: 10.1016/S0002-9440(10)64512-9. View

12.

Negishi Y, Iwabuchi H, Sakunaga H, Sakamoto M, Okabe K, Sato H . Serum and tissue measurements of CA72-4 in ovarian cancer patients. Gynecol Oncol. 1993; 48(2):148-54. DOI: 10.1006/gyno.1993.1026. View

13.

Matsuo A, Negoro T, Seo T, Kitao Y, Shindo M, Segawa H . Inhibitory effect of JTP-59557, a new triazole derivative, on intestinal phosphate transport in vitro and in vivo. Eur J Pharmacol. 2005; 517(1-2):111-9. DOI: 10.1016/j.ejphar.2005.05.003. View

14.

Kiyamova R, Shyian M, Lyzogubov V, Usenko V, Gout T, Filonenko V . Immunohistochemical analysis of NaPi2b protein (MX35 antigen) expression and subcellular localization in human normal and cancer tissues. Exp Oncol. 2011; 33(3):157-61. View

15.

Corut A, Senyigit A, Ugur S, Altin S, Ozcelik U, Calisir H . Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis. Am J Hum Genet. 2006; 79(4):650-6. PMC: 1592565. DOI: 10.1086/508263. View

16.

Zhang M, Cheng S, Jin Y, Zhao Y, Wang Y . Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim Biophys Acta Rev Cancer. 2021; 1875(2):188503. DOI: 10.1016/j.bbcan.2021.188503. View

17.

Aebi S, Castiglione M . Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009; 20 Suppl 4:21-3. DOI: 10.1093/annonc/mdp117. View

18.

Lacerda-Abreu M, Russo-Abrahao T, Queiroz Monteiro R, Rumjanek F, Meyer-Fernandes J . Inorganic phosphate transporters in cancer: Functions, molecular mechanisms and possible clinical applications. Biochim Biophys Acta Rev Cancer. 2018; 1870(2):291-298. DOI: 10.1016/j.bbcan.2018.05.001. View

19.

Li J, Dowdy S, Tipton T, Podratz K, Lu W, Xie X . HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn. 2009; 9(6):555-66. PMC: 3273415. DOI: 10.1586/erm.09.39. View

20.

Yedema C, Massuger L, Hilgers J, Servaas J, Poels L, Thomas C . Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA125 and CA15.3 serum assays. Int J Cancer Suppl. 1988; 3:61-7. DOI: 10.1002/ijc.2910410813. View